Aline Fares
@AlineFaresMD
Medical Oncologist at University of Florida @UFHealthCancer DSG Thoracic Research Lead. Former @pmcancercentre @acccancercenter #lungcancer
Sherlock-Lung: Mutagenesis of LC in Never Smokers (LCNS) @Nature: - 871pt samples - KRAS+ ⬆️3.8x in LCNS’s in USA/EU v Asia - passive smoke not assoc with mtns - air pollution (PM2.5) assoc with p53 & shorter telomeres @OncoAlert #LCSM nature.com/articles/s4158…
1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 nature.com/articles/s4159…
Big congratulations to @KHigginsMD on becoming the new Chair of the NRG Lung Cancer Committee! 🎉 Grateful for the incredible leadership of Dr. Jeff Bradley (2013–2025), whose dedication advanced lung cancer research in countless ways #lcsm #lungcancer @NRGonc @NRGOncology
📈 Impressive NRG progress! From 3/2019 to 2/2025: ✅ 15,310+ patients enrolled in NRG-led trials ✅ 21,339 total accruals across all NCTN studies 📝 1,765 publications (30% high impact) since 2014 Proud to be part! @NRGonc @NRGonc



Great news we were waiting for the OS data for a while #lungcancer #lcsm
🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…
Excited about all the Phase 3 trials and IITs launching in our UF Thoracic Oncology portfolio! Grateful to be part of a team pushing research forward for our lung cancer patients. 🚀🫁 #lcsm #LungCancer #ClinicalTrials @TGeorgeMD
Great presentations at the NRG Translational Science Lung Cancer Workshop !! @NRGonc
Congratulations to UF Health Cancer Center members Drs. Araujo, Fares, Gim and Nicholson, who were selected as members of @NRGonc's Early Career Mentorship Subcommittee, providing an opportunity to develop their skills as clinical investigators: go.ufl.edu/e4eimfi
Discussão bem legal!
How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion with @HaradaGuilherme and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport
🆕 article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases annalsofoncology.org/article/S0923-…
Proud to share our review in Cancer Treatment Reviews: We explore how trial designs are evolving to prioritize safety, biomarkers & patient-centered care. Thanks to Prof. @curijoey and @darioT_ #Oncology #DoseOptimization #CancerTrials @OncoAlert
ADCs: are we dosing them right? Likely not. In this body composition study of 48 patients with mBC receiving T-DXd, higher subcutaneous adipose tissue and higher BMI were associated with a 5-fold increase in dose reductions and reduced T-DXd activity. nature.com/articles/s4152…
Real world outcomes for #EGFR NSCLC with 1L osimertinib @JTOonline from ConcertAI, Flatiron Clinical-Genomics, and COTA databases 2018-22. Overall, median OS 28.6m and 5y OS 18%. Stark reminder that attrition is real: 33% received no 2L therapy. jto.org/article/S1556-…
Always a tall task to debate @bensolomon1, but @ShirishGadgeel and I make the case for personalizing TKI choice in the CROWN era. jto.org/article/S1556-… @ALKPositiveinc #LCSM
⏰ATTENTION ⏰ Patients w/ Lung Cancer ❓Frustrated by common clinical trial barriers ie: -long visits &⏳away from family -💰💵💲 -lack of resources & much more 👇🏽 surveymonkey.com/r/37P79WB ⬆️Consider taking our survey and be part of the CHANGE! @DevikaDasMD @IshwariaMD
Very good review of KRASg12c and others, despite the fact we have drugs for g12c resistance arises soon, we have now PAN KRAS and PAN RAS inhibitors in development and also inhibitors for KRASg12D @KRASKickers #lungcancer #lcsm
KRAS inhibitors: resistance drivers and combinatorial strategies cell.com/trends/cancer/…
Our paper describing the use of an ultrasensitive circulating tumour DNA detection assay to stratify #TRACERx patients with early-stage non-small cell lung cancer pre-operatively for clinical outcome is out today @NatureMedicine. Thread below 👇
Nice to see our new publication in Nature Reviews Clin Oncology on line!